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A B S T R A C T
Successful delivery of inhalation medication to the lungs can be affected by the inhalation manoeuvre
used. Conventional in-vitro testing of the emitted dose from a dry powder inhaler (DPI) uses a vacuum
pump to simulate an inhalation. We have adapted this method by replacing the pump with patient
inhalation proﬁles and an anatomical throat. Three anatomical throat sizes and three inhalation proﬁles
were used. The proﬁles represented the 10th, 50th and 90th percentiles of peak inhalation ﬂow and
acceleration of ﬂow from a population of 50 COPD patients inhaling through empty Spiromax and
Turbuhaler devices. Combining the dose emission results for the three throat sizes, the mean (SD)
budesonide ﬁne-particle dose (FPD) from budesonide–formoterol Spiromax 320/9 mg was 78.91 (20.18),
79.91 (15.36) and 75.10 (19.91) mg and the total emitted dose (TED) of budesonide was 263.69 (40.74),
261.20 (21.65) and 261.61 (45.65) mg. Similarly, the FPD from 320/9 mg Turbuhaler was 22.45 (3.24), 52.20
(12.57) and 69.11 (75.10) mg with a TED of 143.80 (14.90), 149.50 (26.61) and 158.61 (43.04) mg. Spiromax
showed greater consistency than Turbuhaler over a range of inspiratory ﬂow proﬁles. The results
demonstrate the value of this new method to assess the doses that patients receive during real-life use of
their DPI.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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When a drug is inhaled, the dose that is emitted (deﬁned as the
total emitted dose [TED]) from an inhaler is either deposited into
the airways or impacts onto the oropharyngeal region and is
swallowed (Chrystyn, 2000; Laube et al., 2011). Of the drug that isAbbreviations: ACC, acceleration at the beginning of inhalation; BF, budesonide
plus formoterol; COPD, chronic obstructive pulmonary disease; DPI, dry powder
inhaler; FDC, ﬁxed-dose combination; FPD, ﬁne-particle dose; GSD, geometric
standard deviation; HPLC, high-performance liquid chromatography; ICS, inhaled
corticosteroid; IV, inhaled volume; LABA, long-acting beta2-agonist; LOQ, limit of
quantitation; MMAD, mass median aerodynamic diameter; MVIC, Medicon Valley
Inhalation Consortium; NGI, next generation impactor; PIF, peak inspiratory ﬂow;
TED, total emitted dose.
* Corresponding author at: Inhalation Consultancy Ltd, Yeadon, Leeds, Inhalation
Consultancy Ltd., Tarn House, 77 High Street, Yeadon, Leeds LS19 7SP, UK.
Tel.: +44 01274 773590.
E-mail addresses: h.chrystyn@gmail.com (H. Chrystyn),
guilherme.saﬁoti@teva.se (G. Saﬁoti), hans.keegstra@tevapharmachemie.com
(J.R. Keegstra), gokul.gopalan@tevapharm.com (G. Gopalan).
1 Current address: 41 Spruce Hollow Road, Green Brook NJ 08812, USA.
http://dx.doi.org/10.1016/j.ijpharm.2015.05.076
0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article undeposited into the airways, a small fraction is removed by normal
mucociliary clearance and is swallowed. The emitted dose that is
swallowed, or inhaled into the lungs, reaches the systemic
circulation via the gastrointestinal and pulmonary routes, respec-
tively. The drug particle size distribution, measured by in-vitro
methodologies, provides an appreciation of the amount of drug
that will impact onto the oropharyngeal region and the distribu-
tion of the inhaled fraction in the lungs. Part of this distribution is
the ﬁne-particle dose (FPD), typically deﬁned as the quantity of
drug administered as particles of diameter <5 mm (European
Medicines Agency – Committee for Medicinal Products for Human
Use ((CHMP), 2006). The TED is a surrogate maker for systemic
delivery and hence an indicator of systemic safety, while the FPD
and its distribution is an indicator of lung deposition, hence a
marker for efﬁcacy (Fernandez Tena and Casan Clara, 2012; Labiris
and Dolovich, 2003).
The dose, and its particle size distribution, emitted from a dry
powder inhaler (DPI), is determined by the inhalation manoeuvre
performed by the patient, the inhaler and the formulation. There
are differences between devices in the extent to which inhalationder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[ACC], peak inspiratory ﬂow (PIF) and the total inhaled volume
[IV]) affect the delivered dose from a DPI (Atkins, 2005; Virchow
et al., 2008). The inhalation manoeuvre is affected by a wide variety
of factors such as the user’s inspiratory effort and ﬂow, the inhaled
volume and throat geometry (Dolovich and Dhand, 2011; Zhou
et al., 2011). The need for correct inhalation technique is clear;
different patients may ﬁnd some inhalers easier to use, and easier
for them to master the required inhalation technique. However,
published data suggest that a large proportion of patients use a
suboptimal technique when using DPIs (Lavorini et al., 2008;
Molimard, 2005; Thomas and Williams, 2005).
Traditionally, the in-vitro TED and its particle size distribution
via a DPI, which includes the FPD, is measured using standard
pharmacopoeial methods (Council of Europe, 2014; United States
Pharmacopeia, 2014) and is widely accepted by the regulatory
authorities. The method involves simulating an inhalation proﬁle
through a DPI using a vacuum pump to emit a dose and collect it
into a cascade impactor. The measured particle size distributions
represent particle deposition into different zones of the lungs.
Humans cannot replicate the square wave generated by a vacuum
pump; nor can the majority of patients achieve the pharmacopoe-
ia-recommended inhalation parameters for the change in the
pressure inside the inhalation channel of the inhaler or the inhaled
volume (Azouz et al., 2015).
More recently, a method has been proposed that replaces the
vacuum pump used in pharmacopoeial methods with an inhala-
tion proﬁle measured during real-life use when an individual uses
an inhaler (Olsson et al., 2013). The method is an extension of that
described using a mixing inlet (Nadarassan et al., 2010) which
enables zero ﬂow through the inhaler in-situ attached to the
cascade impactor by providing supplementary air into the cascade
impactor at the same ﬂow as the vacuum that is drawn through the
impactor. Replaying an inhalation proﬁle from the supplementary
air supply means that the vacuum pump forcing the ﬂow through
the cascade impactor causes the inhalation proﬁle to be replayed
through the inhaler in-situ (Olsson et al., 2013). This ex-vivo
method, using a patient inhalation proﬁle instead of the vacuum
pump, provides information on the TED and particle size
distribution (which includes the mass median aerodynamic
diameter [MMAD] and the geometric standard deviation [GSD])
that the patient would have inhaled.
We have collected inhalation proﬁles from patients when they
inhaled using empty versions of a Symbicort1 Turbuhaler1
(AstraZeneca, UK) and DuoResp1 Spiromax1 (Teva Pharmaceut-
icals, Israel) and, using an adaption of the ex-vivo method
described by (Olsson et al., 2013), we have measured the emitted
dose characteristics that the patients would have inhaled. Both
these DPIs contained budesonide plus formoterol (BF). DuoRespFig. 1. (A) Experimental setup for generating and replaying inhalation proﬁles. (B) The re
(replayed) proﬁle was recorded and compared with the target proﬁle.(BF) Spiromax DPI was recently developed as an alternative to
Symbicort1 (BF) Turbuhaler1DPI and is approved in the European
Union for use in adult patients (18 years old) with asthma or
chronic obstructive pulmonary disease (COPD) where an inhaled
corticosteroid (ICS)/long-acting beta2-agonist (LABA) is indicated.
The intention when developing the Spiromax device was to
maximise ease of use, potentially leading to improvements in
treatment adherence and eventual clinical outcomes (Barrons
et al., 2011; Lareau and Yawn, 2010; Rand, 2005). Instructions for
using Spiromax, as described in the summary of product
characteristics, describe ‘three simple steps’: open, breathe, close
(Teva Pharma BV, 2014). The device provides patients with
conﬁrmation by taste (lactose) that a dose has been successfully
administered, and a single-increment dose counter provides
further means of monitoring therapy. Comparative studies have
demonstrated pharmacokinetic equivalence of BF Spiromax to BF
Turbuhaler (Weisfeld et al., 2013a, 2013b). Further studies have
shown the delivered dose of BF via Spiromax to be consistent in a
variety of simulated real-world conditions (Arp et al., 2013).
2. Materials and methods
2.1. Overview
Methodology for characterising the emitted dose from a DPI
using the Next Generation Impactor (NGI) replacing the vacuum
pump with a patient’s inhalation proﬁle has been described
previously by Olsson et al. (Olsson et al., 2013). The current in-vitro
study used similar methods to those described by Olsson et al., and
was carried out by Emmace Consulting AB and the Medicon Valley
Inhalation Consortium (MVIC); it was funded by a research grant
from Teva Pharmaceuticals.
2.2. Inhalers
BF Spiromax inhalers (DuoResp, Teva Phamaceuticals, Israel)
used in this study contained high-strength budesonide and
formoterol (labelled, emitted [‘delivered’] dose of 320/9 mg; lot
MD9001) in ﬁxed-dose combination (FDC) and were provided to
MVIC and Emmace by Teva Pharmaceuticals. BF Turbuhalers
(Symbicort, AstraZeneca, UK) containing BF (labelled dose of
320 to 9 mg; lot PASZ) were commercially purchased and also
supplied by Teva Pharmaceuticals.
2.3. Throat geometry models (small, medium, large)
To replicate respiratory tract geometry from a variety of
patients, three anatomically accurate models with small, medium
and large throat dimensions (Olsson et al., 2013) were used.strictor was equivalent to the air ﬂow resistance of the inhaler device. The generated
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International Society of Aerosol Medicine website (International
Society for Aerosols in Medicine, 2012). The same three models
were used in the present study, as well as an inlet speciﬁed by the
United States Pharmacopeia (referred to as the ‘USP throat’). Throat
models were coated with w/w: 3% Brij35 (a nonionic polyoxy-
ethylene surfactant)/68% glycerol/16% ethanol/12% water solution
before testing.
2.4. Selection of inhalation proﬁles (weak, medium, strong)
Experiments were conducted using inhalation proﬁle data from
a crossover study that included 50 COPD patients (Azouz et al.,
2013). Patients performed inhalation manoeuvres with empty
(placebo) versions of both Spiromax and Turbuhaler according to
the respective patient information leaﬂets, with an inhalation
proﬁle recorder attached to each device. Using the 50 inhalation
proﬁles provided, the 10th, 50th and 90th percentiles were
calculated for the PIF (L/min) and ACC (kPa/sec) for both Spiromax
and Turbuhaler. The three inhalation proﬁles closest to each of the
percentiles for both parameters and for each device were selected
and denoted ‘weak’ (10% [10th percentile], ‘medium’ (50% [50th
percentile])) or ‘strong’ (90% [90th percentile]), respectively. The
‘weak’ proﬁle, for example, provided slow ACC and a low PIF,
following the general correlation between these two parameters.
The three inhalation ﬂow-time proﬁles (weak, medium and
strong) were reproduced using a lung simulator comprising a
computer-controlled, servomotor-operated piston in a 5 L cylinder
(F-SIG 6300; FIA AB, Sweden; Fig. 1). Inhalation proﬁles created by
the simulator were measured using a TSI 4040 ﬂow meter (TSI Inc,
Shoreview, MN, USA) and recorded using AmazingFlow (version
1.0; Raketvetenskap, Sweden) software. For accurate reproduction
it was intended that PIF and ACC of the simulated inhalation would
be within 5% of the source proﬁle, and plots of ﬂow against time
were checked visually for consistency. For comparison, tests were
also performed with pharmacopoeia-recommended methodology:
constant pressure drop of 4 kPA (corresponding with a ﬂow rate of
60 L/min for both DPIs) and a 4 L inhalation volume (Council of
Europe, 2014; United States Pharmacopeia, 2014).Fig. 2. Schematic of the experimental setup of the Next GeneraEach throat geometry (i.e., small, medium and large) was tested
with each of the three selected inhalation proﬁles. The USP inlet
was tested using the medium inhalation proﬁle and the
pharmacopoeia methodology (pressure drop, 4 kPa; inhalation
volume, 4 L) only. The medium throat was also used with the
pharmacopoeia-recommended inhalation proﬁle.
2.5. Experimental setup
All experiments were performed at 21–24 C and 30–58%
relative humidity.
2.5.1. NGI setup and parameters tested
Fig. 2 provides a schematic design of the method. The NGI setup
was used to measure the emitted dose and particle size
distribution of the inhalers. A mixing inlet was attached to the
anatomical throat or the USP port at one end and to a pre-separator
at the other end. The purpose of the mixing inlet was to provide
supplementary air at the same ﬂow that was drawn through the
NGI so that air ﬂow through the inhaler mouthpiece was zero. A
ﬂow meter was attached to the supplementary air feed to monitor
the ﬂow. A lung simulator was used to reproduce the selected
inhalation proﬁles (as determined during inhalation proﬁle replay
setup), and a tube connected the lung simulator to the
supplementary air ﬂow between the mixing inlet and the meter.
Using this setup, when an inhalation proﬁle was drawn from the
supplementary air, the inhalation proﬁle was replayed at the
inhaler mouthpiece because of the constant ﬂow of air being
drawn through the NGI. The inhalation proﬁle thus facilitated de-
aggregation and emission of the dose, which was then transported
to the NGI. A computer linked to both the lung simulator (via a
servomotor) and the ﬂow meter allowed for the generation and
monitoring of ﬂow within the system. Five separate doses were
used for each determination. Drug particles deposited on each
stage of the NGI were recovered and analysed by high-performance
liquid chromatography (HPLC). For each inhalation proﬁle,
determinations were made using the small, medium and large
throats (n = 2, 3 and 2, respectively). When the results of the three
throat sizes were combined there were, therefore, seven separatetor Impactor (NGI) for measuring particle size distribution.
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USP throat were also used to determine the characteristics of the
emitted dose using the method described in Fig. 2 with the
standard pharmacopoeia-recommended inhalation proﬁle (pres-
sure drop, 4 kPa; inhalation volume, 4 L drawn by a vacuum pump)
(Council of Europe, 2014; United States Pharmacopeia, 2014). For
these inhalations, three separate dose emission determinations
where made for the medium throat and the USP throat.
The following parameters were measured using the NGI: the
TED, FPD representing particles with an aerodynamic diameter
<5 mm, MMAD and GSD.
2.6. HPLC assay
The amounts of drug recovered on each ﬁlter and stage of the
NGI were obtained using an HPLC assay.
The HPLC method was based on internal standard methodology
and the limit of quantitation (LOQ) was determined as the peak
height corresponding to 10 times the noise level. The LOQ was
estimated as 0.03 mg/mL for formoterol and 0.9 mg/mL for
budesonide. Additional details regarding the method are shown
in Table 1.
3. Results
Graphical representations of the replayed (simulated) inhala-
tion proﬁles were similar to those of the target (source) proﬁles
(Fig. 3). The observed variability between simulated and source
values for PIF and ACC was typically within 1.5% (Table 2). Thus, the
intention for variability to be <5% was fulﬁlled in all cases except
ACC with the weak Turbuhaler proﬁle, mixing inlet setup.
A summary of the dose emission characteristics is presented in
Tables 3 and 4. The dose emission determinations for all the three
anatomical throat is combined in these tables (hence
n = 7 determinations for each throat). Overall trends in the NGI
FPD data indicate greater consistency across inhalation proﬁles
with Spiromax, and greater consistency between different throat
geometries with Turbuhaler (Fig. 4; Tables 3 and 4). The data in
Fig. 4 also suggest that budesonide FPD was comparable between
the two inhalers with the strong inhalation proﬁle. However, with
the medium and particularly the weak inhalation proﬁles, FPD was
numerically higher with Spiromax than with Turbuhaler. Patterns
of variation in FPD were similar with formoterol as with
budesonide. Table 5 (as well as Fig. 4) presents a comparison of
the aerodynamic dose emission characteristics between the
medium anatomical and the USP throat when using the
pharmacopoeia-recommended inhalation proﬁle of 4 kPa with a
4 L inhalation volume provided by a vacuum pump.
NGI analyses showed that MMAD was more consistent across
the study experiments with Spiromax than with Turbuhaler:
Spiromax, 1.98–2.53 mm (budesonide; Table 3) and 1.92–2.53 mm
(formoterol; Table 4); Turbuhaler, 1.95–3.05 and 1.84–3.01 mm,
respectively. The MMAD results with the two inhalers areTable 1
HPLC methodology parameters.
Column Waters XTerra RP18 3.5 mm, 50a 4.6 
Column temperature 25 C
Mobile phase Acetonitrile/25 mM sodium phospha
Flow rate 2.0 mL/min (Dp  155 bar)
Injection volume 25 mL
Detection wavelength, UV 214 nm
Run time 6 min
Diluent 95% ethanol/water 50/50 (vol/vol)
Internal standard Propyl-4-hydroxybenzoate (propagin
a The sodium phosphate buffer was prepared by adjusting 25 mM phosphoripresented graphically in Fig. 5 (budesonide data). For the weak
inhalation proﬁle, MMAD was lower with Spiromax (2.41 mm
[budesonide] and 2.45 mm [formoterol]) vs Turbuhaler (3.05 and
3.01 mm, respectively). Fig. 4 also shows that budesonide GSD
results were similar with both devices across throat geometries
and inhalation proﬁles. The overall range of formoterol GSD values
was slightly higher with Turbuhaler than Spiromax (1.81–2.15 vs
1.72–1.97; Table 4).
The data in Tables 3 and 4 show that TED was higher with
Spiromax than Turbuhaler for both budesonide and formoterol
with all inhalation proﬁles and at 4 kPa. Similarly, Fig. 4 shows that
the TED of budesonide was higher with the Spiromax device. This
was also true for formoterol.
4. Discussion
The present results show that this novel methodology is
valuable for assessing doses that patients are likely to receive in
clinical practice when using a DPI. A higher degree of dose
consistency was demonstrated with BF Spiromax than BF
Turbuhaler over a range of inhalation ﬂow proﬁles. FPD and TED
were numerically higher with Spiromax than Turbuhaler, particu-
larly with the weak inhalation proﬁle. With both inhalers,
budesonide TED was below the labelled quantity with all three
replayed inhalation proﬁles, although at a constant 4 kPa the
Spiromax TED approached the labelled quantity.
It is widely accepted that a minimum inspiratory ﬂow rate of
30 L/min is required to ensure sufﬁcient de-aggregation of a drug
or drug combination by the Spiromax and Turbuhaler DPIs, to
ensure adequate deposition of the drug into the lungs (Al-Showair
et al., 2007; Azouz et al., 2015; Keating and Faulds, 2002), but
higher rates of around 60 L/min (4 kPa) are preferred (Chrystyn,
2003; de Boer et al., 1997; Kanabuchi et al., 2011; Keating and
Faulds, 2002; Pauwels et al., 1997; Thomas and Williams, 2005).
The weak COPD patient inhalation proﬁle used in our study
represents the proportion of patients from the Azouz study
(Azouz et al., 2013) with a PIF rate of 30–35 L/min and an ACC
rate of <5 kPa/s. Although these patients represent a small
proportion of the COPD patient population in the Azouz study (i.
e., are within the 10th percentile), they are more likely than
medium- and strong-inhalation patients to have a lower
inspiratory potential, and they may also have more comorbidities
affecting their ability to use an inhaler correctly. As a result, these
patients may have fewer options in terms of maintenance-therapy
inhalers available to them, so an inhaler that is easy to use
correctly is important. In our study, as mentioned above,
Turbuhaler performance was affected by changes in inhalation
proﬁle. These results support ﬁndings from other studies showing
that Turbuhaler is ﬂow-dependent (Tarsin et al., 2004) and is more
ﬂow-dependent than other DPIs such as the Diskus1 (Palander
et al., 2000). Indeed Turbuhaler performed least well when the
weak inhalation proﬁle was applied; and this was observed across
the different throat geometries.mm
te buffer, pH 3.0a + 15 mM sodium octanesulphonic acid, 30/70 (vol/vol)
, IS) 25 mg/mL
c acid to pH 3.0 with 1.0 M sodium hydroxide.
Fig. 3. Experimental set up: selected (source) and replayed (simulated) ﬂow proﬁles via the Spiromax and Turbuhaler inhalers using 10th (weak), 50th (medium) and 90th
(strong) percentile inhalation proﬁles. The aim was to achieve an acceptable match between the replayed proﬁles (via the breathing simulator) and selected proﬁles (from
COPD patient proﬁles): (A) BF Spiromax weak proﬁle, (B) BF Spiromax medium proﬁle, (C) BF Spiromax strong proﬁle, (D) BF Turbuhaler weak proﬁle, (E) BF Turbuhaler
medium proﬁle, (F) BF Turbuhaler strong proﬁle.
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formoterol obtained with Spiromax using the weak, medium and
strong inhalation proﬁles were lower than the labelled emitted
dose of 320/9 mg. It is important to note that the values for TED
(as well as the other NGI parameters) represent predictions of
the dose that would reach the patient’s lungs in clinical practice.
The pharmacopoeial method may be considered as a quality
control test with only partial representation of clinical practice
because it uses a square wave generated by a vacuum pump. In
real life, the actual acceleration of the ﬂow from the inhalationmanoeuvre is lower than the acceleration of the ﬂow provided
by a vacuum pump; therefore, most patients do not achieve
the inhalation volume of 4 L (Azouz et al., 2015). This is the
most likely reason for the difference observed between the
pharmacopeial and inhalation proﬁle. Using the pharmacopoeial
method, the medium throat and the USP throat provided a
TED for Spiromax close to the labelled emitted dose whereas
with the Turbuhaler device, only the USP throat provided a
TED value close to the labelled emitted dose. Further inves-
tigations are required to assess whether the differences observed
Table 2
Peak inspiratory ﬂow (PIF), acceleration values, and inhalation volume for target (source) and replayed (simulated) proﬁles.
Inhalation proﬁle PIF (L/min) Acceleration (L/sec2) Inhalation volume (L)
Patient Lung simulator Difference (%) Patient Lung simulator Difference (%) Target volume Patient* Lung simulator* Difference** (%)
Spiromax
Weak 34 34 0 1.2 1.2 0 1.9 1.9 1.9 0
34 0 1.1 1.4
Medium 54 54 0 2.2 2.2 0.8 1.4 1.4 1.4 –1.4
55 1.8 2.2 1.5
Strong 84 85 1.2 4.6 4.5 1.1 2.3 2.3 2.3 –1
85 1.2 4.4 2.6
Turbuhaler
Weak 29 29 0 0.6 0.6 2.8 1.6 1.7 1.7 –1.2
29 0 0.6 5.6
Medium 51 51 0 1.9 1.9 1.7 1.1 1.1 1.1 –1
51 0 1.9 0.9
Strong 67 68 1.5 4.9 4.9 0 2.5 2.5 2.5 1
66 1.5 5.1 2.7
* Mean volumes of three consecutive replays of the target proﬁles.
** Difference = patient–lung simulator.
Table 3
Mean (SD) aerodynamic dose emission characteristics of budesonide using the NGI
using the adapted in-vitro methodology. The anatomical throat results are the
combined data for the three different sizes (small, medium and large) (n = 7). Cells
shaded grey indicate parameters not tested.
Anatomical throata
(n = 7) USP inlet (n = 3)
Parameter Turbuhaler Spiromax Turbuhaler Spiromax
Weak inhalation
proﬁle (10th
percentile
[10%])
TED 143.80
(14.90)
263.69
(40.74)
FPD 22.45
(3.24)
78.91
(20.18)
MMAD 3.05
(0.32)
2.41
(0.24)
GSD 1.77
(0.11)
1.62
(0.04)
Medium
inhalation
proﬁle (50th
percentile
[50%])
TED 149.50
(26.61)
261.20
(21.65)
209.92
(6.90)
284.88
(28.60)
FPD 52.20
(12.57)
79.91
(15.36)
74.29
(2.91)
116.79
(11.05)
MMAD 2.30
(0.17)
2.07
(0.19)
2.66
(0.10)
2.53
(0.10)
GSD 1.82
(0.05)
1.74
(0.03)
1.89
(0.05)
1.74
(0.03)
Strong
inhalation
proﬁle (90th
percentile
[90%])
TED 158.61
(43.04)
261.61
(45.65)
FPD 69.11
(29.18)
75.10
(19.91)
MMAD 1.95
(0.22)
1.98
(0.27)
GSD 1.86
(0.08)
1.86
(0.07)
a Data are mean and SD for small, medium and large throats. FPD, ﬁne-particle
dose (mg); GSD, geometric standard deviation; MMAD, mass median aerodynamic
diameter (mm); NGI, Next Generation (pharmaceutical) Impactor; TED, total
emitted dose (mg); USP, United States Pharmacopeia.
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device itself.
TED values obtained with the Turbuhaler demonstrated the
expected dependence on ﬂow rate, and were much lower than the
labelled emitted dose (Tarsin et al., 2004; Palander et al., 2000).
Turbuhaler TED values only approached labelled values when using
the pharmacopoeial method with the USP throat. On another note,
our study suggested the possibility of drug being retained within thedevice when the ﬂow rate is low, and that retained drug may be
released to create a high dose when normal ﬂow rates are restored.
However, the likelihood of this occurring in clinical practice appears
low, because ﬂow rates are almost always >25 L/min. Furthermore,
theTurbuhaler isdesigned toclearresidualdose left insidethedevice
during the opening and closing of the cap.
As previously mentioned, COPD patients are liable to have
reduced inhalation capacity when the need for symptom control is
greatest (e.g. during an exacerbation, when rapid control is
needed) (Broeders et al., 2004; Rau, 2006). An inhaler with greater
dose consistency at reduced inhalation rates could be advanta-
geous in this situation. It should be noted, however, that although
disease severity is an important consideration, age and its
associated risk factors may actually be more important than
severity as a predictor of inspiratory ﬂow (Malmberg et al., 2010).
On the other hand, greater sensitivity to throat geometry suggests
a wider range of inter-patient dosing regimens is required. Such
requirements should become apparent early during therapy and
not be a complication once appropriate dosing has been
established.
The three anatomical throat geometries used in our study were
developed using information from an earlier study where
investigators created magnetic resonance imaging outputs of
adult volunteers’ throats while they inhaled from experimental
devices (Pritchard and McRobbie, 2004). The medium throat
proﬁle used in our study was selected to represent typical lung
delivery, while the small and large throats were selected to provide
an indication of possible inter-subject variability (Olsson et al.,
2013). We found that changing the throat geometry from small to
medium-to-large throat had little effect on the dose with
Turbuhaler (particularly with medium-to-large throat) as long
as the weak inhalation proﬁle was not used. This suggests that
Turbuhaler is less affected by differences in throat geometry
compared with Spiromax. In contrast, Spiromax appeared to
operate optimally when the large throat was used. However, the
differences are small and unlikely to be clinically relevant. Without
detailed scans, it is not possible to identify a patient’s throat size in
routine clinical practice and the data for a medium throat size
should be referred to.
The MMAD of the aerosol predicted to reach the lungs was
similar for the two inhalers except with the weak inhalation
proﬁle, for which MMAD was lower with Spiromax. An MMAD
<5 mm is considered to be necessary for sufﬁcient airway
deposition (Roche et al., 2013), while lower values, 1.5 mm, are
Table 4
Mean (SD) aerodynamic dose emission characteristics of formoterol using the NGI using the adapted in-vitro methodology. The anatomical throat results are the combined
data for the three different sizes (small, medium and large) (n = 7). Cells shaded grey indicate parameters not tested.
Anatomical throata USP inlet
Parameter Turbuhaler Spiromax Turbuhaler Spiromax
Weak inhalation proﬁle TED 4.63 (1.08) 7.50 (1.26)
(10th percentile [10%]) FPD 0.94 (0.08) 2.14 (0.63)
MMAD 3.01 (0.25) 2.45 (0.26)
GSD 2.15 (0.14) 1.78 (0.17)
Medium inhalation proﬁle TED 4.52 (0.83) 7.29 (0.41) 5.70 (0.06) 7.53 (0.68)
(50th percentile [50%]) FPD 1.76 (0.36) 2.39 (0.41) 2.09 (0.09) 2.88 (0.23)
MMAD 2.14 (0.10) 2.05 (0.15) 2.44 (0.09) 2.53 (0.11)
GSD 2.03 (0.04) 1.95 (0.05) 2.04 (0.07) 1.92 (0.01)
Strong inhalation proﬁle TED 4.73 (1.10) 7.38 (1.00)
(90th percentile [90%]) FPD 2.24 (0.81) 2.19 (0.41)
MMAD 1.84 (0.19) 1.92 (0.27)
GSD 2.0 (0.06) 1.97 (0.08)
a Data are mean and SD for small, medium and large throats. FPD, ﬁne-particle dose (mg); GSD, geometric standard deviation; MMAD, mass median aerodynamic diameter
(mm); NGI, Next Generation (pharmaceutical) Impactor; TED, total emitted dose (mg); USP, United States Pharmacopeia.
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airways (Usmani et al., 2005). However, MMAD values <1 mm may
be lost when the patient exhales (Hess, 2008). MMAD values in our
study ranged between 1.5 and 3.5 mm, for both drugs with both
devices. FPD results were consistent with the MMAD outcomes,Fig. 4. Mean ﬁne-particle dose (FPD) (A) and total emitted dose (TED) (B) of budesoni
inhalation proﬁles.Spiromax FPD being higher than Turbuhaler FPD with the weak
inhalation proﬁle. These ﬁndings imply that inhaled medication
from either Spiromax or Turbuhaler should usually reach the lungs
as intended, but that patients with low inhalation rates may
receive a higher lung dose from BF Spiromax versus BF Turbuhaler,de with BF Spiromax and BF Turbuhaler and when using the different throats and
Table 5
Mean (SD) aerodynamic dose emission characteristics using the NGI for the pharmacopeia recommended method with the medium anatomical throat and the USP throat
((n = 3) determinations for each throat).
Medium anatomical throat USP throat
Parameter Turbuhaler Spiromax Turbuhaler Spiromax
Budesonide TED 171.12 (10.15) 310.86 (29.09) 231.12 (9.20) 299.96 (6.61)
FPD 94.15 (8.76) 96.3 (21.46) 123.01 (5.81) 121.52 (9.58)
MMAD 2.12 (0.04) 2.10 (0.11) 2.68 (0.09) 2.48 (0.01)
GSD 1.77 (0.01) 1.72 (0.20) 1.76 (0.03) 1.72 (0.02)
Formoterol TED 4.73 (0.15) 8.28 (0.81) 6.32 (0.10) 7.35 (0.31)
FPD 2.86 (0.16) 2.31 (0.51) 3.35 (0.06) 2.46 (0.18)
MMAD 1.95 (0.04) 2.04 (0.04) 2.57 (0.07) 2.48 (0.02)
GSD 1.94 (0.02) 1.72 (0.11) 1.81 (0.02) 1.78 (0.01)
FPD, ﬁne-particle dose (mg); GSD: geometric standard deviation; MMAD: mass median aerodynamic diameter (mm); NGI: Next Generation (pharmaceutical) Impactor;
SD: standard deviation; TED: total emitted dose (mg); USP: United States Pharmacopeia.
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tissue. GSD results indicated similar levels of budesonide dose
consistency with the two inhalers, but higher formoterol dose
consistency with Spiromax versus Turbuhaler. This difference is
more likely to relate to differences in particle size distribution of
the formoterol ‘raw material’ than performance of the inhalers.
Clinical investigation has shown that BF Spiromax 160/4.5 mg is
noninferior to BF Turbuhaler 200/6 mg in asthma patients
(Virchow et al., 2014). Such demonstration that Spiromax is at
least as effective as Turbuhaler is consistent with the dose
emission characteristics of the two devices, although some degree
of clinical beneﬁt with Spiromax versus Turbuhaler might be
expected. Clinical trials are ongoing, and results from the ELIOT
study (EU Clinical Trials Register, 2013) are eagerly awaited.
However, it should be remembered that clinical studies do notFig. 5. Mean of the mass median aerodynamic diameter (MMAD) (A) and geometric stan
using the different throats and inhalation proﬁles.reﬂect real-life use due to the close monitoring of patients as well
as strict inclusion and exclusion criteria.
The main strength of this study is the use of methodology
showing that patient inhalation proﬁles can be used in vitro to
characterise the dose that the patient would receive during real-
life use of the inhaler. The inclusion of a range of throat anatomies
and inhalation proﬁles from real COPD patients represent further
strengths. This approach should have optimised the extent to
which our in-vitro ﬁndings are applicable in vivo. The limitations of
our study include lack of investigation of the exhaled fraction, and
the inclusion of only one dose (320/9 mg) of BF Spiromax and BF
Turbuhaler. As with any in-vitro study, clinical data are required to
conﬁrm the implications of this study’s ﬁndings.
In conclusion, Spiromax showed greater consistency than
Turbuhaler over a range of inspiratory ﬂow proﬁles and a tendencydard deviation (GSD) (B) for budesonide with BF Spiromax and BF Turbuhaler, when
276 H. Chrystyn et al. / International Journal of Pharmaceutics 491 (2015) 268–276towards higher FPDs at low inhalation rates. The results conﬁrm
the value of the novel methodology used in the study. However,
further studies are required to conﬁrm the clinical implications of
these data.
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